Despite the insights on the consequence of the loss of wild type p53 on cell metabolism, the impact of mutant p53 variants on the metabolic processes of pancreatic cancer remains not well understood, and the potential implications of these regulatory alterations in tumorigenesis are not fully elucidated. The gene discussed is TP53; the disease is familial pancreatic carcinoma.